Form 4: Mirum Pharmaceuticals Director Patrick Heron Reports Stock Purchases

Director Patrick Heron reported purchases of Mirum Pharmaceuticals (MIRM) common stock through Frazier Life Sciences X, L.P. and Frazier Life Sciences IX, L.P.

Summary

• Patrick Heron, a director of Mirum Pharmaceuticals, reported purchases of common stock on March 4th and 5th, 2025.
• The purchases were made indirectly through Frazier Life Sciences X, L.P. and Frazier Life Sciences IX, L.P.
• On March 4th, 1,279 shares were purchased at a weighted average price of $45.5486, and 56 shares were purchased at a weighted average price of $45.9597.
• On March 5th, 267 shares were purchased at a price of $44.545.
• Following these transactions, Frazier Life Sciences X, L.P. beneficially owns 163,910 shares, and Frazier Life Sciences IX, L.P. beneficially owns 3,566,912 shares.
• Heron disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the filing itself is a routine disclosure.

Positives

• The director's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders (directors, officers, or those owning more than 10% of a company's shares) buy or sell the company's securities.

Stakeholder Impact

• The stock purchases by a director could positively influence shareholder confidence.

Key Dates